Intellia Therapeutics temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release. The ...
Intellia Therapeutics Inc. shares dropped after the company said a patient died after suffering liver damage in a clinical trial for the company’s gene-editing treatment. The patient, who was in his ...
After the deaths of three patients, the maker of an investigational gene therapy stopped shipments of the drug after it refused a request from the U.S. Food and Drug Administration (FDA) to pull the ...
Clinical Trials Arena on MSN
Sarepta to investigate immunosuppressant Elevidys combo to avoid fatal AEsAcute liver injury has been associated with the death of two non-ambulatory DMD patients treated with Elevidys.
MedPage Today on MSN
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 YearsEtranacogene dezaparvovec meets the benchmarks for success, researcher says ...
A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback